Payment overview · 2025
General Payments
$1,207.11
56 reported records · 21 companies
Healthcare provider profile · identity verified
Dennis A Cortes, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MIRAMAR, FL · NPI 1013198118
Verified facts
What the public records show
CMS Open Payments records show Dennis A Cortes, MD received $1,207.11 in general payments during 2025 across 56 reported records.
PFIZER INC. accounted for 14.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $169.46 | 14.0% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $164.34 | 13.6% | 7 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $143.67 | 11.9% | 6 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $107.01 | 8.9% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $74.26 | 6.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $69.34 | 5.7% | 4 | 2025 |
| Medicure Pharma Inc. | Unresolved — no canonical attribution shown | $57.58 | 4.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $48.65 | 4.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $48.33 | 4.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $41.44 | 3.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.33 | 3.3% | 2 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $35.90 | 3.0% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.78 | 2.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $29.94 | 2.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.49 | 2.2% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.72 | 2.0% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $23.57 | 1.9% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $19.80 | 1.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.32 | 1.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.20 | 1.3% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $15.98 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,207.11 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $169.46 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $150.40 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $146.63 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $143.67 | 6 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $107.01 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $74.26 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $69.34 | 4 | 2025 |
Source payment records
|
|||||
| Zypitamag Normalized: zypitamag |
Drug | Medicure Pharma Inc. | $57.58 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $53.45 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.40 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $48.65 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $48.33 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $41.44 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $40.33 | 2 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $35.90 | 2 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $35.90 | 2 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $35.90 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $33.78 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $29.94 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $26.49 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $24.72 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $15.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 171 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
171 | 45 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 694 | 213 |
| Atorvastatin Calcium | Atorvastatin Calcium | 603 | 154 |
| Losartan Potassium | Losartan Potassium | 565 | 169 |
| Levothyroxine Sodium | Levothyroxine Sodium | 536 | 142 |
| Metformin Hcl | Metformin Hcl | 412 | 118 |
| Omeprazole | Omeprazole | 410 | 126 |
| Simvastatin | Simvastatin | 404 | 137 |
| Carvedilol | Carvedilol | 385 | 114 |
| Gabapentin | Gabapentin | 374 | 104 |
| Clonazepam | Clonazepam | 337 | 60 |
| Alprazolam | Alprazolam | 310 | 67 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 310 | 112 |
| Furosemide | Furosemide | 261 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 255 | 78 |
| Citalopram Hbr | Citalopram Hydrobromide | 245 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 231 | 70 |
| Lisinopril | Lisinopril | 227 | 53 |
| Azithromycin | Azithromycin | 218 | 150 |
| Methylprednisolone | Methylprednisolone | 211 | 147 |
| Meloxicam | Meloxicam | 198 | 84 |
| Eliquis | Apixaban | 171 | 45 |
| Famotidine | Famotidine | 169 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 169 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 165 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 142 | 46 |
| Potassium Chloride | Potassium Chloride | 141 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 129 | 52 |
| Montelukast Sodium | Montelukast Sodium | 123 | 43 |
| Trazodone Hcl | Trazodone Hcl | 122 | 30 |
| Temazepam | Temazepam | 119 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 116 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 113 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 30 |
| Risperidone | Risperidone | 110 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 106 | 59 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 101 | 81 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 101 | 19 |
| Tramadol Hcl | Tramadol Hcl | 101 | 37 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 94 | 42 |
| Hydralazine Hcl | Hydralazine Hcl | 92 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 83 | 12 |
| Lorazepam | Lorazepam | 82 | 15 |
| Cephalexin | Cephalexin | 80 | 62 |
| Alendronate Sodium | Alendronate Sodium | 78 | 29 |
| Sertraline Hcl | Sertraline Hcl | 75 | 18 |
| Glipizide | Glipizide | 74 | 25 |
| Bupropion Xl | Bupropion Hcl | 72 | 23 |
| Donepezil Hcl | Donepezil Hcl | 72 | 17 |
| Nifedipine Er | Nifedipine | 71 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 24 |
| Ibuprofen | Ibuprofen | 64 | 24 |
| Mirtazapine | Mirtazapine | 62 | 12 |
| Metformin Hcl Er | Metformin Hcl | 61 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 23 |
| Glipizide Er | Glipizide | 58 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 21 |
| Allopurinol | Allopurinol | 55 | 18 |
| Acyclovir | Acyclovir | 54 | 24 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 54 | 33 |
| Oxybutynin Chloride | Oxybutynin Chloride | 54 | suppressed |
| Synthroid | Levothyroxine Sodium | 54 | 17 |
| Lovastatin | Lovastatin | 53 | 19 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 53 | 11 |
| Valsartan | Valsartan | 53 | 14 |
| Levetiracetam | Levetiracetam | 52 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 27 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 45 | 14 |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 42 | suppressed |
| Atenolol | Atenolol | 41 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 28 |
| Memantine Hcl | Memantine Hcl | 41 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 41 | 11 |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Glimepiride | Glimepiride | 40 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 37 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 14 |
| Olanzapine | Olanzapine | 36 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Spironolactone | Spironolactone | 34 | 11 |
| Topiramate | Topiramate | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 17 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | 13 |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 31 | 11 |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 29 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Ciclopirox | Ciclopirox | 27 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 15 |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 24 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 24 | 14 |
| Latanoprost | Latanoprost | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 23 | suppressed |
| Prednisone | Prednisone | 23 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | 12 |
| Mometasone Furoate | Mometasone Furoate | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Premarin | Estrogens, Conjugated | 21 | 11 |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 19 | 11 |
| Amoxicillin | Amoxicillin | 19 | 11 |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 15 |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 12 |
| Irbesartan | Irbesartan | 15 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Xanax | Alprazolam | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,207.11 · 56 records | PFIZER INC. | AIRSUPRA, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, Flector, GLYCATE, JOURNAVX, Kerendia, Leqembi, Licart, MOUNJARO, NP Thyroid 60, NURTEC ODT, Ozempic, RELTONE 200 MG, RELTONE 400 MG, Rybelsus, Symbravo, Tirosint, Tlando, VOQUEZNA, VRAYLAR, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE, Zypitamag | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error